Compare Cassava Sciences Inc (FLNA) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Remitly Global Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Remitly Global Inc trades at $25.64 (market cap $5.26B). The key difference: Remitly Global Inc is far larger — about 99× Cassava Sciences Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | RELY | |
|---|---|---|
Market Cap | $53.14M | $5.26B |
Sector | Health | Technology |
52-Week High | $4.64 | $24.96 |
52-Week Low | $1.09 | $12.20 |
Enterprise Value | -$33.43M | $4.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
RELY stock trades at $25.57, up 8.72% in the last 24 hours, showing strong momentum. The company demonstrates accelerating revenue growth from $654M in 2022 to $1.64B in 2025, with net income turning positive at $67.93M. Technical indicators show bullish momentum with the current price near resistance at $26. Recent expansion into UAE and Canadian markets positions the company for continued international growth.
RELY presents a compelling growth story with improving profitability and strong analyst support (92% buy ratings). However, elevated valuation multiples (P/E 52) and competitive pressures in the remittance space warrant caution. The stock's upside potential to the $27.40 consensus target appears reasonable given accelerating revenue and expanding margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
